Nona Biosciences Does Agreement with AstraZeneca for Monoclonal Antibody

Nona Biosciences inks license and option agreement with AstraZeneca for monoclonal antibody to be developed into novel tumour targeted therapies

Overview

Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced that it has entered into a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

Terms of the Sgreement

• Under the terms of the agreement, Nona Biosciences shall receive US$ 19 million upon completion of the transaction. 
• Nona is eligible to receive an additional US$ 10 million in potential near-term milestone payments and up to US$ 575 million upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales. 
• In addition, Nona is eligible to receive payments for the option programs should AstraZeneca exercise these options.

Words from MD: Nona Biosciences

• "We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumour targeted therapies, to maximize the potential of our novel antibodies,” said Jingsong Wang, M.D., Ph.D., chairman of Nona Biosciences. 
• “This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients.”

From AstraZeneca

Puja Sapra, senior vice president, tumour targeted delivery, oncology R&D, AstraZeneca, said: “The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona’s innovative biologics discovery engine into novel tumour targeted therapies using AstraZeneca’s industry-leading capabilities.”

Nona Biosciences

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!